TriangleEpcoritamab + Ibrutinib (NCT06536049)
Epcoritamab + Ibrutinib trial for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT06536049). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for adults with aggressive B cell non-Hodgkin lymphoma, such as diffuse large B cell lymphoma, that has come back or not responded to treatment.
The idea: combine epcoritamab and ibrutinib. Epcoritamab is a bispecific antibody, given as a shot under the skin, that binds CD3 on T cells and CD20 on lymphoma cells at the same time, bringing them together. Ibrutinib is a daily pill.
The study looks at safety, the best dose, and how well it works.
This phase 1 and 2 study plans 38 patients. At Ohio State University Comprehensive Cancer Center in Columbus, Yazeed Sawalha leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.